Author

Peng Yang

China Pharmaceutical UniversityORCID 0000-0002-2613-941XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Ahmed HasaniD· 1 shared Aleksandra OlowiD· 1 shared Barbara Rath· 1 shared Bruce Huang· 1 shared Cindy Li· 1 shared David Bauché· 1 shared Dawei WangiD· 1 shared Essam MetwallyiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ahmed HasanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 15, 2025

YAP/TEAD4-regulated placental alkaline phosphatases ALPP and ALPPL2 are immunosuppressive ectonucleotidases modulated by MAPK inhibitors

J MARTIN, Bruce Huang, Tobias Ehrenberger…·David Bauché

This study identifies YAP/TEAD4 as a regulator of ALPP/L2 expression and shows that MAPK inhibitors enhance their expression, improving ADC efficacy through immunomodulation.

DOI 10.1101/2025.10.15.682438

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 7, 2024

Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy

Wenbin Kuang, Jinxin Jiang, Xiao Wang…·Peng Yang

This study identifies PTPN2 as a therapeutic target in AML, discovers a selective inhibitor K73, and demonstrates its efficacy in reducing AML burden in vitro and in vivo.

2 citations

humanexperimental assay

𝕏 PostBluesky